Epizyme (NASDAQ:EPZM) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Epizyme (NASDAQ:EPZM) from a sell rating to a hold rating in a report released on Wednesday, BidAskClub reports.

Other equities research analysts have also issued reports about the company. ValuEngine upgraded Epizyme from a strong sell rating to a sell rating in a research report on Friday, November 1st. Cowen restated a buy rating and set a $18.00 price target on shares of Epizyme in a research report on Thursday, October 31st. HC Wainwright restated a buy rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, Zacks Investment Research lowered Epizyme from a hold rating to a sell rating and set a $11.00 price target on the stock. in a research report on Monday, October 21st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $17.50.

Shares of NASDAQ EPZM traded up $0.78 during trading hours on Wednesday, hitting $15.18. 722,400 shares of the company’s stock were exchanged, compared to its average volume of 811,703. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.83 and a beta of 2.40. Epizyme has a 1-year low of $5.14 and a 1-year high of $16.59. The company’s 50-day moving average price is $10.98 and its 200-day moving average price is $12.39. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.90 and a quick ratio of 10.90.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.11. The business had revenue of $5.72 million for the quarter, compared to analyst estimates of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. On average, research analysts expect that Epizyme will post -1.89 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Institutional investors and hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC bought a new position in Epizyme in the 2nd quarter valued at $2,511,000. HarbourVest Partners LLC bought a new position in Epizyme in the 2nd quarter valued at $177,000. TD Asset Management Inc. boosted its position in Epizyme by 7.0% in the 2nd quarter. TD Asset Management Inc. now owns 21,394 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 1,400 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Epizyme by 20.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 459,308 shares of the biopharmaceutical company’s stock valued at $5,765,000 after buying an additional 77,012 shares during the last quarter. Finally, Alps Advisors Inc. bought a new position in Epizyme in the 2nd quarter valued at $2,386,000. Hedge funds and other institutional investors own 86.32% of the company’s stock.

About Epizyme

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

See Also: Special Dividends

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Leave a Reply

Your email address will not be published. Required fields are marked *

*